Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.
About Carisma Therapeutics Inc.
Carisma Therapeutics Inc. (NASDAQ: CARM) is a clinical-stage biopharmaceutical company pioneering the development of transformative immunotherapies through its proprietary chimeric antigen receptor macrophage (CAR-M) and monocyte cell engineering platform. Headquartered in Philadelphia, Pennsylvania, Carisma is at the forefront of advancing next-generation cell therapies to address critical unmet medical needs in oncology, fibrosis, and autoimmune diseases.
Innovative Cell Therapy Platform
Carisma's proprietary platform focuses on engineering macrophages and monocytes, a subgroup of white blood cells critical to both the innate and adaptive immune responses. Unlike traditional CAR-T therapies, which target lymphocytes, Carisma's approach leverages the unique properties of myeloid cells to infiltrate solid tumors, modulate the tumor microenvironment, and address antigen heterogeneity. This innovative platform has enabled the development of both ex vivo (outside the body) and in vivo (inside the body) therapies, positioning the company as a leader in macrophage-based immunotherapy.
Core Therapeutic Areas
- Oncology: Carisma's lead programs focus on addressing HER2-overexpressing solid tumors through CAR-Macrophage and CAR-Monocyte therapies. These programs aim to overcome the limitations of existing cell therapies by enhancing tumor infiltration, persistence, and manufacturing efficiency.
- Fibrosis: The company is advancing preclinical programs targeting liver fibrosis, including conditions like metabolic-associated steatohepatitis (MASH). Engineered macrophages in these programs aim to reduce fibrosis and inflammation while restoring key cellular processes.
- Autoimmune Diseases: Through an expanded collaboration with Moderna, Carisma is exploring the potential of in vivo macrophage engineering to address autoimmune conditions, leveraging its deep expertise in myeloid biology.
Strategic Collaborations
Carisma has established a strategic partnership with Moderna, Inc., combining Carisma's expertise in macrophage engineering with Moderna's mRNA and lipid nanoparticle (LNP) platform. This collaboration has yielded promising in vivo CAR-M candidates targeting oncology and autoimmune diseases, including a development candidate for hepatocellular carcinoma (HCC). These partnerships underscore Carisma's commitment to innovation and scalability.
Market Position and Competitive Edge
In a competitive landscape dominated by CAR-T and other immune cell therapies, Carisma differentiates itself with its focus on macrophages and monocytes. This approach addresses key challenges in treating solid tumors, such as tumor microenvironment immunosuppression and antigen heterogeneity. Additionally, its pivot to in vivo therapies represents a strategic shift toward off-the-shelf solutions, potentially reducing manufacturing complexities and costs.
Operational Focus and Future Outlook
Carisma recently reprioritized its pipeline to focus on high-potential in vivo programs in oncology, fibrosis, and autoimmune diseases. This strategic realignment, coupled with a streamlined workforce, reflects the company's commitment to operational efficiency and long-term innovation. With multiple preclinical and clinical milestones anticipated in the coming years, Carisma is well-positioned to deliver transformative therapies that redefine treatment paradigms.
Conclusion
Carisma Therapeutics Inc. represents a paradigm shift in cell therapy, leveraging macrophage and monocyte engineering to tackle some of the most challenging diseases. Through its innovative platform, strategic collaborations, and focused pipeline, Carisma is poised to make a significant impact in the fields of oncology, fibrosis, and autoimmune diseases, offering hope to patients with limited treatment options.
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company's Co-founder and Chief Scientific Officer, Michael Klichinsky, PharmD, PhD, will be presenting at the conference on Tuesday, February 25 at 10:30 am ET.
Interested parties can access an audio webcast of the presentation through the Company's Investor Events section on their Investor Relations webpage. The recording will remain available for a time after the event.
Carisma Therapeutics (Nasdaq: CARM), a pioneer in macrophage-focused therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Steven Kelly, President and CEO, will represent the company at the conference on Tuesday, February 11 at 4:40 pm ET.
The presentation will be accessible via audio webcast through the Company's Investor Events section on their Investor Relations webpage, with -time archive availability following the event.
Carisma Therapeutics (NASDAQ: CARM) announced a strategic restructuring, including discontinuation of CT-0525 development and a 34% workforce reduction. The company will redirect focus to its in vivo macrophage engineering platform for fibrosis, oncology, and autoimmune disease therapies.
Key developments include: plans to nominate a liver fibrosis development candidate in Q1 2025; ongoing collaboration with Moderna on multiple oncology and autoimmune programs; and expected restructuring costs of approximately $2.7 million. Three senior executives, including the CFO, General Counsel, and SVP of Human Resources, will depart by December 31, 2024.
The decision to discontinue the anti-HER2 program was based on competitive landscape assessment and recent developments in anti-HER2 therapies affecting antigen loss/downregulation.
Carisma Therapeutics (Nasdaq: CARM), a clinical-stage biopharmaceutical company specializing in immunotherapies, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. Steven Kelly, President and CEO, will engage in a fireside chat on December 5th at 9:35 am ET. The event will be accessible via audio webcast on the company's Investor Relations webpage under the Investor Events section, with -time archive availability.
Carisma Therapeutics (NASDAQ: CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The research shows that macrophages can be genetically engineered to target specific pathways in liver disease using factors like TIM4, relaxin, and IL10. A single dose of TIM4-expressing macrophages, alone or with relaxin, significantly reduced liver fibrosis in the CDAHFD MASH model. The engineered cells were well-tolerated and outperformed non-engineered cells. The company plans to nominate a development candidate for its liver fibrosis program in Q1 2025.
Carisma Therapeutics (NASDAQ: CARM) announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed with Moderna. The therapy demonstrated ability to create CAR-M directly in vivo, reprogramming myeloid cells to target GPC3-expressing cancer cells. Pre-clinical results showed specificity for GPC3 tumor antigen with dose-dependent cytotoxicity against GPC3+ tumor cells. In both syngeneic and humanized tumor models, the therapy significantly reduced tumor burden and suppressed liver metastasis. The treatment was well-tolerated in mouse models, showing promise as an off-the-shelf treatment for GPC3+ solid tumors, including HCC.
Carisma Therapeutics reported Q3 2024 financial results with cash and cash equivalents of $26.9 million, expected to fund operations into Q3 2025. Research and development expenses decreased to $11.3 million from $19.6 million year-over-year. The company anticipates initial results from the Phase 1 study of CT-0525 in Q1 2025 and plans to nominate a development candidate for its liver fibrosis program in the same quarter. New preclinical data for anti-GPC3 CAR-M therapy and liver fibrosis will be presented at upcoming scientific meetings. The company recently expanded its collaboration with Moderna to include autoimmune disease targets.
Carisma Therapeutics (Nasdaq: CARM) announced new pre-clinical data presentation on their anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC) at SITC 2024. The therapy, developed with Moderna, uses lipid nanoparticles to deliver mRNA that reprograms endogenous myeloid cells, creating an off-the-shelf treatment approach for GPC3+ solid tumors.
The data, demonstrating robust anti-tumor activity, will be presented on November 8, 2024, at the SITC Annual Meeting in Houston, Texas. The presentation focuses on targeting Glypican-3, a tumor-associated antigen commonly expressed in HCC. Two posters will be presented, including one on the pre-clinical efficacy of anti-GPC3 CAR-M and another on a Phase 1 study of anti-HER2 CAR therapy.
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors. Sohanya Cheng, MBA will join the board effective October 31, 2024, while Michael Torok will step down on the same date due to other professional commitments. Board Chair Sanford Zweifach highlighted Cheng's experience in oncology, leadership, strategic planning, and commercialization as valuable assets for advancing the company's portfolio. Cheng expressed enthusiasm about supporting Carisma's mission in developing innovative immunotherapies and strengthening its position in engineered macrophages.
Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company, has announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 2024 in Houston, Texas, from November 6-10. The company will present two posters:
1. Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma (Publication Number: 329)
2. A Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors (Publication Number: 659)
Both presentations are scheduled for Friday, November 8, 2024, at the Exhibit Halls A B George R. Brown Convention Center. The posters will be available on Carisma's website in the 'Publications' section following the start of the poster session.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
What does Carisma Therapeutics specialize in?
How does Carisma differentiate itself from traditional cell therapy companies?
What is the significance of Carisma's collaboration with Moderna?
What are Carisma's key therapeutic areas?
What challenges does Carisma address in cancer treatment?
What is the company's approach to fibrosis treatment?
What is the potential of Carisma's in vivo therapies?
What is the significance of Carisma's pivot to in vivo therapies?
What are the risks associated with Carisma's business model?
Where is Carisma Therapeutics headquartered?
